GlassScriptPhysician profile
Kenneth J Fitzpatrick
NPI 1669407748
$3,350.92
in general payments reported to CMS, 2019-2025
29 companies · $49.84 in 2025
The $49.84 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,795 · 2020: $507 · 2021: $358 · 2022: $249 · 2023: $392 · 2025: $49.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $377 · Education: $65.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $377.32 |
| Education | $65.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $847.29 | 2019-2023 | Xtandi |
| Janssen Biotech, INC. | $262.97 | 2019-2023 | Erleada |
| Ferring Pharmaceuticals INC. | $256.87 | 2019 | |
| Dendreon Pharmaceuticals LLC | $234.44 | 2019-2023 | Provenge |
| Abbvie INC. | $195.12 | 2019-2021 | |
| Antares Pharma, INC. | $192.77 | 2019-2023 | Tlando, Xyosted, Nocdurna |
| Endo Pharmaceuticals INC. | $168.81 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $157.37 | 2019-2023 | |
| Boston Scientific Corporation | $148.46 | 2019-2025 | Lithovue |
| Merck Sharp & Dohme LLC | $103.75 | 2019-2023 | Lynparza, Keytruda, Welireg |
| Tolmar, INC. | $94.56 | 2023 | |
| Pfizer INC. | $93.49 | 2019-2023 | |
| Tolmar Pharmaceuticals, INC. | $86.20 | 2019-2022 | |
| Urovant Sciences INC | $75.98 | 2022 | |
| Teleflex LLC | $69.01 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $53.57 | 2019 | |
| Mission Pharmacal Company | $41.05 | 2019 | |
| Blue Earth Diagnostics | $37.13 | 2019 | |
| Coloplast Corp | $34.40 | 2019 | |
| Dentsply Ih INC. | $30.53 | 2019 | |
| Olympus America INC. | $22.55 | 2022 | |
| Avadel Specialty Pharmaceuticals, LLC | $21.39 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $19.91 | 2022 | |
| Sumitomo Pharma America, INC. | $19.75 | 2023 | Gemtesa |
| Halozyme INC | $18.59 | 2023 | |
| Neotract INC. | $17.95 | 2020 | |
| Medtronic USA, INC. | $16.69 | 2019 | |
| Metuchen Pharmaceuticals | $15.72 | 2019 | |
| Aytu Biopharma, INC. | $14.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Fitzpatrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.